智通财经APP获悉，科济药业-B(02171)午后涨超6%，截至发稿，涨5.24%，报16.06港元，成交额1939.9万港元。
消息面上，科济药业公布，旗下CT071用于治疗新诊断的多发性骨髓瘤(NDMM)研究者发起的临床试验研究结果摘要，已被2025年欧洲血液学协会(EHA)年会接受，将在壁报展示环节进行发布。
据介绍，CT071用于治疗复发/难治多发性骨髓瘤或复发/难治浆细胞白血病(PCL)。一项研究者发起的临床试验正在中国开展，旨在初步评估CT071治疗复发/难治多发性骨髓瘤或浆细胞白血病的安全性和有效性。另一项研究者发起的试验正在中国开展，用于治疗新诊断的多发性骨髓瘤(NDMM)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.